Accuracy Analysis of Hong Kong Embryo Genetic Testing: PGT-A and PGT-M Technical Indicators and Clinical Data
The accuracy of Hong Kong embryo genetic testing (PGT) is influenced by factors such as the technical platform, embryo mosaicism ratio, and number of biopsied cells. The accuracy of PGT-A aneuploidy screening is approximately 97-99%, while the accuracy of PGT-M for single-gene disorders, after pedigree verification, is about 98-99%. This article analyzes the real accuracy data, technical limitations, and clinical significance of Hong Kong embryo genetic testing from a reproductive medicine perspective, helping those planning pregnancy set realistic expectations.
The accuracy of Hong Kong embryo genetic testing (PGT) needs to be evaluated by type: PGT-A (aneuploidy screening) using NGS technology has an accuracy of approximately 97-99% for detecting chromosomal numerical abnormalities, but there is a 1-3% false positive rate and a 1-2% false negative rate, mainly affected by the embryo mosaicism ratio and limitations of the biopsied cells; PGT-M (single-gene disorder testing) has an accuracy of about 98-99% after pedigree verification, dropping to 90-95% without verification; PGT-SR (structural rearrangement testing) has an accuracy of approximately 95-98%. Test results must be interpreted in conjunction with embryo morphological grading and clinical conditions, and 100% accuracy is not guaranteed. Several reproductive laboratories in Hong Kong hold CAP/CLIA international certifications, with quality control systems consistent with European and American standards.
I. Accuracy of Hong Kong Embryo Genetic Testing: Data by Type and Clinical Interpretation
Hong Kong embryo genetic testing, medically known as Preimplantation Genetic Testing (PGT), is divided into three types based on the testing purpose, each with different accuracy indicators. The following data is based on clinical statistics from multiple internationally certified reproductive laboratories in Hong Kong, with the primary technical platform being Next-Generation Sequencing (NGS).
| Test Type | Test Target | Accuracy Range | Main Influencing Factors |
|---|---|---|---|
| PGT-A | Chromosomal aneuploidy (numerical abnormalities) | 97% - 99% | Mosaicism ratio, representativeness of biopsied cells, amplification efficiency |
| PGT-M | Single-gene disorders (e.g., thalassemia, cystic fibrosis) | 98% - 99% (after pedigree verification) |
Completeness of pedigree verification, gene locus coverage, quality of haplotype analysis |
| PGT-SR | Chromosomal structural rearrangements (balanced translocations, inversions, etc.) | 95% - 98% | Complexity of rearrangement type, precision of breakpoint mapping |
It is important to clarify that the above accuracy rates refer to the consistency between the test result and the true genetic status of the embryo, not the live birth rate after transfer. Embryos with normal PGT results may still fail to implant or result in miscarriage after transfer due to other factors (e.g., endometrial receptivity, maternal immune status).
II. Root Causes of Accuracy Differences: Technical Platforms and Biological Limitations
The accuracy of embryo genetic testing cannot reach 100%, mainly due to constraints at the following four levels.
2.1 Embryo Mosaicism – The Core Challenge to Accuracy
Mosaicism refers to an embryo having both chromosomally normal and abnormal cells. Studies show that approximately 15%-30% of blastocysts exhibit varying degrees of mosaicism. Biopsy only takes 3-5 trophectoderm cells. If the sample happens to consist of normal or abnormal cell populations, the result may be inconsistent with the overall state of the embryo.
- Low-level mosaicism (<20%): The test result may be reported as normal, posing a risk of false negatives.
- High-level mosaicism (>50%): The test result may be reported as abnormal, but the embryo may have self-correction capabilities, posing a risk of false positives.
- Clinical management: Most laboratories in Hong Kong label embryos with a mosaicism ratio between 20%-50% as "mosaic embryos" and recommend deciding on transfer in conjunction with genetic counseling.
2.2 Limitations in the Representativeness of Biopsied Cells
Embryo biopsy takes cells from the trophectoderm (which develops into the placenta), not from the inner cell mass (which develops into the fetus). Although the two are highly genetically consistent, in rare cases (approximately 1%-2%), discrepancies may exist. This means that even for embryos with normal test results, there is still a very low possibility of chromosomal abnormalities in the fetus.
2.3 Sources of Technical Error
- DNA amplification failure or preferential amplification: Whole genome amplification from a single cell may involve allele dropout (ADO), with an incidence of about 1%-3%.
- Sample contamination: Maternal cell or environmental DNA contamination can interfere with results. Laboratories control the contamination rate to below 0.5% through strict quality control.
- Platform resolution limitations: NGS has lower sensitivity for detecting small fragment deletions/duplications (<1Mb) compared to large fragment abnormalities.
2.4 Embryo Self-Correction and Its Limitations
Some embryos with chromosomal abnormalities have self-correction mechanisms during development (e.g., trisomy rescue), but the incidence is very low (<1%). This situation can lead to an abnormal biopsy result but a normal final fetus, or vice versa.
III. Impact of Age on Embryo Chromosomal Abnormality Rate
Female age is the most significant factor affecting the rate of embryonic chromosomal abnormalities, which is also the key reason for the differing clinical value of PGT-A across different age groups. The following data comes from cumulative clinical statistics from Hong Kong reproductive centers:
| Female Age | Embryo Chromosomal Abnormality Rate (approx.) | Proportion Screenable by PGT-A | Clinical Benefit Assessment |
|---|---|---|---|
| ≤35 years | 20% - 30% | ~25% | Moderate benefit; decision should consider embryo number |
| 36 - 38 years | 30% - 45% | ~35% | Higher benefit |
| 39 - 40 years | 45% - 55% | ~45% | Significant benefit |
| 41 - 42 years | 55% - 70% | ~55% | Significant benefit, but consider number of available embryos |
| ≥43 years | 70% - 85% | ~65% | Significant benefit, but number of available embryos may be insufficient |
Note: The above data represent population trends; individual variation is significant. The proportion screenable by PGT-A depends on the success rate of embryo biopsy and the interpretability of test results.
The older the age, the greater the absolute benefit of PGT-A, but it also faces the challenges of fewer retrieved oocytes and an insufficient number of embryos available for biopsy. For women over 42, approximately 30%-40% of cycles may have no embryos passing PGT-A testing.
IV. Easily Overlooked Details in Hong Kong Embryo Genetic Testing
In clinical consultations, the following details are often overlooked by those planning pregnancy but directly affect the correct understanding of test results.
4.1 Timing of Testing: Blastocyst Biopsy vs. Cleavage Stage Biopsy
Mainstream reproductive centers in Hong Kong perform biopsies at the blastocyst stage (day 5-6 after fertilization), taking 3-5 trophectoderm cells. Compared to cleavage stage (day 3) biopsy, blastocyst biopsy yields more cells, has a lower rate of misdiagnosis due to mosaicism, and has less impact on embryo development. Accuracy data is based on blastocyst stage biopsy.
4.2 "Interpretability Rate" of Test Results
Approximately 3%-5% of biopsy samples cannot produce a definitive result due to DNA amplification failure, substandard signal quality, or contamination. The incidence of this in Hong Kong laboratories is about 2%-4%, requiring discussion with the clinician about whether to re-biopsy or transfer an embryo without PGT.
4.3 Transfer Value of Mosaic Embryos
Mosaic embryos are not absolutely untransferable. For embryos with a mosaicism ratio below 40%, the live birth rate after transfer is approximately 30%-45% (lower than the 50%-60% for normal embryos), but the rates of miscarriage and birth defects are not significantly increased. In Hong Kong genetic counseling, the decision to transfer a mosaic embryo requires a comprehensive assessment of the mosaicism type, ratio, the couple's chromosomal karyotypes, and previous reproductive history.
4.4 Pedigree Verification Requirements for PGT-M
Before PGT-M testing, blood sample genetic verification of both partners and the proband (if there is an affected child) must be completed to establish an effective haplotype analysis system. Performing embryo testing without completing pedigree verification will reduce the accuracy from 98%-99% to 90%-95%. All centers in Hong Kong that offer PGT-M require pedigree verification to be completed first.
V. Common Patient Misconceptions About Embryo Genetic Testing
Based on years of clinical consultation experience, the following misconceptions most easily lead to decision-making bias or imbalanced psychological expectations.
Believing PGT can detect all genetic problems. Standard PGT-A only detects chromosomal numerical and common structural abnormalities; it does not detect microdeletions/microduplications (unless specifically designed), mitochondrial diseases, or epigenetic abnormalities. PGT-M only detects specific known pathogenic genes.
Equating a normal PGT result with a 100% healthy baby. A normal PGT result only indicates that the embryo's chromosomal number and structure show no abnormalities (or does not carry the target pathogenic gene). The fetus may still experience new mutations, intrauterine development issues, birth defects, etc. (overall risk approximately 3%-5%).
Ignoring the possibility of transferring mosaic embryos. Some patients consider mosaic embryos as "abnormal" and discard them directly. In reality, specific types of low-level mosaic embryos have the potential for a healthy live birth after transfer, especially when no euploid embryos are available for transfer.
Believing PGT can replace prenatal diagnosis. Even for embryos with normal PGT results, prenatal diagnosis (amniocentesis or chorionic villus sampling) is still recommended after transfer to confirm the fetal chromosomal status. PGT is a screening technology; prenatal diagnosis is the gold standard.
VI. Clinical Interpretation of PGT Accuracy by Reproductive Specialists
From a clinical reproductive medicine perspective, the "accuracy" of PGT needs to be understood from two dimensions: technical accuracy and clinical effective accuracy.
Technical accuracy refers to the consistency between the laboratory test result and the true state of the embryo, i.e., the aforementioned 97%-99%. Clinical effective accuracy refers to the ongoing pregnancy rate (beyond 12 weeks) after transferring a PGT-normal embryo. Data reported by various Hong Kong centers is approximately 50%-65%. This value is influenced by factors such as female age, embryo morphological grading, and uterine environment, and is not equivalent to technical accuracy.
Doctors consider the following factors comprehensively when making decisions:
- Female age and ovarian reserve function
- History of previous embryonic chromosomal abnormalities or miscarriages
- Chromosomal karyotypes of both partners (e.g., presence of balanced translocations)
- Number and quality of embryos obtained in the current cycle
- Specific type and ratio of mosaic embryos
For patients with a low number of available embryos (<3), doctors may recommend direct transfer without PGT, as the biopsy and freeze-thaw process can cause approximately 5%-10% embryo loss. This decision requires a trade-off between genetic risk and embryo loss.
VII. Answers to Frequently Asked Questions
Q1: How long does it take from embryo biopsy to receiving results for Hong Kong embryo genetic testing?
After blastocyst biopsy, the sample undergoes whole genome amplification, library construction, and NGS sequencing. The entire process takes approximately 14-21 days. Including subsequent genetic counseling and embryo cryopreservation, the total cycle from egg retrieval to obtaining PGT results and arranging transfer is about 2-3 months.
Q2: Does PGT testing damage the embryo?
Blastocyst biopsy takes 3-5 trophectoderm cells and does not damage the inner cell mass (which develops into the fetus). Studies show that the freeze-thaw survival rate of blastocysts after biopsy is approximately 90-95%, not significantly different from non-biopsied blastocysts. However, biopsied embryos must be cryopreserved and cannot be transferred in a fresh cycle.
Q3: Does an abnormal PGT result mean the embryo is absolutely unusable?
Not necessarily. Embryos with chromosomal numerical abnormalities (e.g., trisomy, monosomy) are generally not recommended for transfer. However, mosaic embryos and embryos with certain chromosomal structural abnormalities (e.g., balanced translocation carriers) may have transfer value after genetic counseling assessment. The decision depends on the specific abnormality type, ratio, and clinical situation.
Q4: Is there a difference in PGT accuracy among different reproductive centers in Hong Kong?
Differences mainly depend on the laboratory's technical platform and certification system. Laboratories certified by CAP (College of American Pathologists) or CLIA (Clinical Laboratory Improvement Amendments) have quality control standards aligned with international norms, and accuracy differences are typically within 1-2 percentage points. It is recommended to choose a center with clear international certification and an annual testing volume exceeding 500 embryo cycles.
Q5: Can miscarriage still occur after transferring an embryo with a normal PGT-A result?
Yes. PGT-A cannot screen for all causes of miscarriage. Chromosomally normal embryos can still miscarry due to factors such as endometrial receptivity, maternal immune factors, endocrine abnormalities, infection, or the embryo's own developmental potential. The miscarriage rate for PGT-A normal embryos is approximately 10-15% (slightly increasing with age), which is lower than the miscarriage rate for unscreened embryos (20-30%).
Doctor's Advice
Embryo genetic testing is an important technical tool in the field of assisted reproduction, but it is not a "foolproof" guarantee. When deciding whether to undergo PGT, consider the following points:
- Clarify the testing purpose: Is it for screening chromosomal abnormalities (PGT-A), targeting a known single-gene disorder (PGT-M), or addressing chromosomal structural rearrangements (PGT-SR)? Different types have their own accuracy rates and applicable scenarios.
- Understand the technical boundaries: Accuracy is not 100%. There are technical risks such as mosaicism, amplification failure, and sample contamination. Test results need to be interpreted in conjunction with genetic counseling and clinical conditions.
- Assess your own conditions: Age, ovarian reserve, previous reproductive history, and the number of embryos are core factors influencing the clinical benefit of PGT. When the number of available embryos is low, weigh the potential loss from testing against the potential benefit.
- Maintain prenatal diagnosis: Regardless of the PGT result, standard prenatal diagnosis (amniocentesis or chorionic villus sampling) is still recommended after pregnancy. This is the gold standard for confirming the fetal chromosomal status.
- Choose a qualified laboratory: Confirm whether the laboratory holds CAP, CLIA, or equivalent international certifications, and inquire about its annual testing volume, quality control system, and genetic counseling team configuration.
0 comments